UroGen CEO Liz Barrett shares highlights of the recent Phase 3 ENVISION trial readout in bladder cancer

blonca9
Jun 25, 2024
1 min read

She describes how patients might benefit from UroGen's gel based technology that keeps chemotherapy locally in the bladder vs having recurring surgeries.

Recent Posts

See All

On its 10-year anniversary, Arcus Biosciences is taking its 4th molecule into pivotal studies. Co-Founder & CEO Terry Rosen talks HIF-2⍺, TIGIT, and CD73

Siren Biotechnology is using an online platform to raise up to $5 million from the public in a "community round" - it might be a new avenue of funding for biotech companies

Theravance Biopharma has a key pivotal trial readout scheduled for late '25 / early '26 in symptomatic neurogenic orthostatic hypotension (nOH) in patients with multiple system atrophy (MSA)

UroGen CEO Liz Barrett shares highlights of the recent Phase 3 ENVISION trial readout in bladder cancer

Recent Posts

Join the BiotechTV mailing list

Follow BiotechTV

Sponsors

Sponsor Spotlight